Q2 FY2026 EarningsQ2 FY26 results significantly beat revenue consensus at $7.88M vs. $3.0M expected, driven by a $7.5M preclinical milestone from the BI collaboration. However, Diluted EPS of -$24.14 missed the -$1.69 consensus by a wide margin, primarily due to non-cash charges: a $90M loss on warrant liabilities and $35.1M in license acquisition costs for CUE-221. Despite the earnings miss, a subsequent July 2026 private placement raising $49.8M extends the cash runway through mid-2027.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cue BioPharma(CUE) the Revenue is 7.877 M (+166.7%), Beat estimate;the EPS is -24.14 (-794.1%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B166.66%
0.00B1.56%
+0.00B165.10%
EBIT
TBA--
-0.01B36.65%
----
EPSMiss expectations
-24.14794.07%
-1.6937.41%
-22.4500831.48%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf